Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis

  • Richard N Greenberg, 
  • Yadira Hurley, 
  • Dinh V. Dinh, 
  • Serena Mraz, 
  • Javier Gomez Vera, 
  • Dorothea von Bredow, 
  • Alfred von Krempelhuber, 
  • Siegfried Roesch, 
  • Garth Virgin, 
  • Nathaly Arndtz-Wiedemann


10 Nov 2015: Greenberg RN, Hurley MY, Dinh DV, Mraz S, Vera JG, et al. (2015) Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLOS ONE 10(11): e0142802. View correction



Replicating smallpox vaccines can cause severe complications in individuals with atopic dermatitis (AD). Prior studies evaluating Modified Vaccinia Ankara virus (MVA), a non-replicating vaccine in humans, showed a favorable safety and immunogenicity profile in healthy volunteers.


This Phase II study compared the safety and immunogenicity of MVA enrolling groups of 350 subjects with AD (SCORAD ≤ 30) and 282 healthy subjects.


Subjects were vaccinated twice with MVA, each dose given subcutaneously 4 weeks apart. Adverse events, cardiac parameters, and the development of vaccinia virus humoral immune responses were monitored.


The overall safety of the vaccine was similar in both groups. Adverse events affecting skin were experienced significantly more often in subjects with AD, but the majority of these events were mild to moderate in intensity. Seroconversion rates and geometric mean titers for total and neutralizing vaccinia-specific antibodies in the AD group were non-inferior compared to the healthy subjects.


The size of the study population limited the detection of serious adverse events occurring at a frequency less than 1%.


MVA has a favorable safety profile and the ability to elicit vaccinia-specific immune responses in subjects with AD.

Trial Registration NCT00316602


Smallpox is caused by Variola virus (VARV), an orthopoxvirus of the Poxviridae family. The disease was declared eradicated in 1980 by the World Health Organization (WHO). Serious concerns about the re-emergence of VARV persist and have led the US government to assess the potential reoccurrence of smallpox as a major bioterrorism threat [1.2].

Traditional smallpox vaccines contain replication-competent vaccinia virus (VACV), an orthopoxvirus related to VARV [1,2]. These vaccines are administered via scarification to the skin, causing a localized VACV infection that elicits a protective immune response to VARV. Although these vaccines are highly effective, their replication-competent nature can cause morbidity or even mortality. Skins complications include progressive vaccinia, eczema vaccinatum (EV), generalized vaccinia and autoinoculation [35].

Individuals with eczema, Atopic Dermatitis (AD) or a history of these conditions are at an increased risk of developing EV [68]. Historically, EV occurred at a rate of 39 cases per million vaccinations in the general population and was not limited to the vaccine recipients as contact transmission of VACV is possible [4,5]. Virus shedding following vaccination places individuals in contact with vaccine recipients at risk; there is evidence that EV may be more severe in contacts compared to vaccine recipients [4,911]. These observations led the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices to advise against the use of traditional smallpox vaccines in individuals with skin disorders including eczema, active AD, a history of eczema or AD, and individuals who have household contacts with skin disorders.

The prevalence of skin disorders like AD or eczema could pose a serious challenge to any large-scale vaccination program that relies upon traditional smallpox vaccines. A recent survey of eczema prevalence in the USA found that as many as 31.6 million individuals met the empirical definition of eczema (i.e., itching and inflamed rash, excessive dryness, skin fold location, symptoms lasting ≥ 14 days, or associated with a physician diagnosis of asthma or of allergic rhinitis or hay fever) and 17.8 million met the more rigorous criteria for AD [12]. Further complicating any smallpox vaccination program is the observation that individual recollections regarding a history of eczema or AD are unreliable. Studies suggest that 20–40% of individuals do not report that they or a close contact suffered from eczema or AD, even when medical records confirm the contrary [13,14]. Given the various contraindications (e.g. AD, HIV infection), up to 25% of the population would have to be excluded from vaccination [15]. Therefore there remains a need for a vaccine that can be used in individuals at increased risk of developing severe vaccine related complications.

MVA was used during the 1970s in more than 120,000 people for priming prior to administration with a traditional smallpox vaccine [16,17]. MVA was derived from the parental VACV, chorioallantois vaccinia Ankara, and essentially became replication restricted to avian and certain non-human mammalian cells [18]. MVA is being developed as a safer stand-alone smallpox vaccine. Clinical studies so far have shown that MVA is well tolerated in healthy adults and those with HIV and induces immune responses comparable to traditional smallpox vaccines [1923]. These clinical data are supported by similar findings in animal models [2427]. Sera from MVA vaccinated subjects neutralize VARV [28]. In a phase I clinical trial, subjects with mild AD tolerated MVA well and had humoral immune responses comparable to responses in healthy individuals [23]. We report the results of a Phase II clinical trial more thoroughly investigating the safety and immunogenicity of MVA in individuals with mild to moderate AD or a history of AD. The primary objective of the trial was to assess the humoral immune response induced by MVA in subjects with diagnosed atopic dermatitis compared to healthy subjects measured by an enzyme-linked immunosorbent assay (ELISA). The primary hypothesis is that the humoral immune response of the group with diagnosed atopic dermatitis was not statistically inferior compared to the group with healthy subjects, using the seroconversion rate measured with ELISA 2 weeks after the second vaccination with MVA as the primary endpoint. The main secondary safety objective was to detect all adverse events in the atopic dermatitis group with an incidence of at least 1:100 with at least 95% probability. Other secondary objectives were the comparison of safety and reactogenicity in both groups.


Study design and subjects

MVA smallpox vaccine (IMVAMUNE) was produced by IDT Biologika GmbH (Dessau-Roßlau, Germany) according to GMP and provided by Bavarian Nordic A/S (Kvistgaard, Denmark) in aliquots of 0.5 ml liquid-frozen vaccine containing at least 1 x 108 TCID50/ml. Subjects were immunized at Weeks 0 and 4 by subcutaneous injection of a 0.5 ml dose.

This controlled, open-label Phase II study was conducted under an FDA IND. Enrollment of 18–40 year old vaccinia-naïve volunteers took place at 17 sites in the USA and 7 sites in Mexico, all according to Good Clinical Practice and the principles of the Declaration of Helsinki.

Subjects enrolled in the control group were healthy without any history of atopy; subjects enrolled for the group under investigation were diagnosed with AD. The latter included subjects with a documented history of AD with no symptoms for at least one year prior to enrollment, as well as subjects with active AD having a SCORAD ≤ 30 [29]. The first subject was screened in July 2006. The last screening took place in January 2009, the last regular study visit in April 2009 and the last follow up visit in October 2009.

The protocol was approved by independent ethics committees for each site and all volunteers provided written informed consent prior to participation in the clinical trial. Approval was granted by the following committees: Comité de Investigación. para Estudios en Humanos, Puente de Piedra No.150, Col. Toriello Guerra, Tlalpan Mexico City, Mexico 14050; Comité de Ética del Instituto Dermatológico de Jalisco, Avenida Federalismo Norte 3120 Col. Atemajac del Valle Zapopan, Jalisco, Mexico 45190; Comité de Ética de la Unidad de Investigación en Salud de Chihuahua, Ortiz Mena 2200, Fracc. Las Palmas, Chihuahua, Chih. Chihuahua 31205; Comité de Investigación y Bioética del Hospital Adolfo López Mateos, Av. Universidad No. 1321, Col. Florida Mexico City, Mexico City 01030; Comité de Investigación y Ética de la Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González" Universidad Autónoma de Nuevo León, Av. Francisco I. Madero Pte s/n y Av.Gonzalitos s/n. Col. Mitras Centro Monterrey, Nuevo León 64460; Comité de Ética e Investigación del Hospital Juárez de México, Av. Instituto Politécnico Nacional #5160, Col. Magdalena de las Salinas, Mexico DF, CP 07760; Comité de Ética del Hospital "Doctor Ángel Leaño", Av. Dr. Ángel Leaño #500 Esq. Av. Juan Gil, Col. Los Robles, Zapopan, Jalisco, CP 45200; University of Kentucky Office of Research Integrity and Institutional Review Board, 315 Kinkead Hall, University of Kentucky; Lexington, KY 40506; IntegReview IRB, 3001 S. Lamar Blvd., Suite 210 Austin, TX 78704; Saint Louis University IRB, 3556 Caroline Street; Caroline Bldg C110, St. Louis, MO 63104; and the Northwestern University IRB, Rubloff Hall, 7th Floor; 750 N. Lake Shore Dr., Chicago, IL 60611.

Safety assessments

Safety assessments were conducted upon screening and at each of five visits during an 8 week active study period: study visits at weeks 0 (vaccination 1), 1, 4 (vaccination 2), 6 and 8. A follow-up (FU) visit or phone call was performed 28 weeks after the second vaccination. Solicited adverse events (AEs) constituted a set of pre-defined, expected local reactions and systemic symptoms. Solicited AEs were recorded on a diary card for the 8-day period following each vaccination. Unsolicited AEs were all events reported by the subject within a 29-day period after each vaccination but not already solicited in the diary card. Any cardiac symptom or electrocardiogram (ECG) change which was determined to be clinically significant and any cardiac enzyme elevation above normal were defined as AEs of special interest (AESI); cardiac enzymes were measured routinely two weeks after each vaccination. ECG assessments were performed at screening, week 1 and week 6. Any AEs that prevented daily activities or body temperatures ≥ 39°C were defined as Grade ≥ 3.

Immunogenicity assays

Blood was drawn at baseline prior to the first vaccination, 1 week and 4 weeks after the first, as well as 2 weeks and 4 weeks after the second vaccination. A sub-group of subjects had a follow-up sample drawn at least 26 weeks after their first vaccination.

Assays for ELISA and plaque reduction neutralization test (PRNT) are described in detail by Overton et al [30]. For the PRNT a different the detection limit (15) than described by Overton et al [30] was used.

Statistical methods

The safety analysis was based on the full analysis set (FAS) consisting of all subjects who received at least one vaccine dose. The immunogenicity analysis was performed on the per-protocol analysis set (PPS) comprising all subjects without major protocol violations. All protocol violations were carefully reviewed on a case-by-case basis; major violations included missed visits, missed vaccinations, missing ELISA titer data, immunosuppressive conditions or severity of illness that were exclusion criteria in the protocol, other vaccinations within 14 days of study vaccination, errors in vaccine preparation, or participation in other studies.

All statistical analyses were performed using SAS. AEs were summarized using frequency tables and differences between groups were tested using Fisher’s exact test. For the primary endpoint analysis an exact 95% confidence interval for the difference in ELISA seroconversion rates between healthy and AD subjects was calculated. If the lower limit of the interval was above -5%, then non-inferiority was concluded. A similar secondary analysis was conducted on the PRNT seroconversion rate differences. Differences in GMT were also tested using a homoscedastic t-test based on the log10 titers. If the lower limit of the confidence interval was above -0.176 (corresponding to a factor 1.5) for ELISA, or -0.301 (corresponding to a factor 2) for PRNT, then non-inferiority of the AD subjects to the healthy subjects was concluded.

The sample size calculation was based on the primary immunogenicity endpoint MVA-specific seroconversion rate. Assuming a significance level of 5%, a power of >80%, and an expected seroconversion rates of 99% in both groups, a sample size of 124 per group (248 in total) was estimated. In order to account for about 5% drop out rate, a total of 130 subjects per group (260 in total) were planned to be treated. However, in order to meet the safety objective of the trial, i.e. to detect adverse events with an incidence of at least 1:100 with 95% probability, a total of 350 subjects were recruited in the AD group. In order to then best compare the safety profile of the AD group to the healthy group, it was intended to recruit a roughly equal amount of healthy subjects; however, it was also planned that the recruitment would stop once 350 subjects had been recruited into the AD group.


Study population

Three hundred and fifty AD subjects and 282 healthy subjects who had not been previously vaccinated against smallpox were enrolled (Table 1). 222 subjects in the AD group (63.4%) had active disease at the time of screening (Table 2). All 632 subjects received at least one dose of the MVA smallpox vaccine. Fig 1 displays the disposition of subjects. Follow-up data were collected by a telephone contact 28 weeks after the second vaccination for 321 AD and 272 healthy subjects. For a subset of 76 AD and 94 healthy subjects there was an on-site visit to collect serum for immunogenicity studies.

Fig 1. Disposition of subjects.

AD = atopic dermatitis; n = number of subjects in the specified category; FAS = full analysis set; PPS = per-protocol analysis set. a: There was one subject that did not receive the second vaccination but did not terminate the study prematurely, i.e. returned for the final visit. b: more than one reason per subject possible. c: 10 subjects with currently active AD had a SCORAD >30 at screening; 2 of these subjects had a SCORAD >39 and were excluded from PPS as major protocol violations. For the volunteers that were excluded from the PPS but had samples available, immunogenicity results were similar to those of the PPS subjects.

Subject demographics and SCORAD status

Mean age, height and weight were similar in both groups. Some differences between the groups were observed in ethnic origin and gender distribution (Table 1). The mean SCORAD value of subjects with a SCORAD >0 was 18.6 ± 8.29 at screening, i.e. mild to moderate disease (Table 2). At Week 8 the number of subjects with a SCORAD > 0 was lower and their mean SCORAD was 15.7 ± 8.61, suggesting that MVA did not exacerbate the underlying disease.

Safety and reactogenicity

Overview of adverse events (AEs).

An overview of the incidence of all AEs is presented in Table 3. No case of death, EV or myopericarditis occurred. There was no statistically significant difference in the frequency of AESI in both groups. The trial had been designed to detect, with a 95% probability, any safety signal occurring with a frequency of at least 1%. During the active study period, three subjects experienced a total of four serious AEs. Only one event, extraocular muscle paresis in a healthy subject, was considered as probably related to the study vaccine. One healthy subject was withdrawn from the study due to several AEs (arthralgia, nausea, abdominal pain) considered unlikely related to the study vaccine. AD subjects experienced causally related AEs more frequently than healthy subjects (67.4% vs 59.6%; p = 0.046, Table 3). However, this difference was mostly due to events of mild and moderate intensity. There was no statistically significant difference between the two groups in the proportion of subjects with Grade ≥ 3 causally related AEs (7.7% vs 5.7%; p = 0.343; AD vs healthy).

Table 3. Subjects Experiencing at Least One Unsolicited or Solicited Adverse Events (FAS, N = 632).

Solicited adverse events.

As expected, most subjects in both groups experienced at least one solicited local AE (injection site pain, injection site erythema or injection site swelling, Table 4). Local AEs were most often of Grade 1 intensity except for injection site pain, which was experienced by most individuals with Grade 2 or 3 intensity. Statistically significant differences between the groups were seen for injection site erythema (p = 0.004) and injection site swelling (p = 0.005). Solicited systemic AEs (Table 5) were more frequent in subjects diagnosed with AD (70.1%) compared to healthy subjects (56.4%), a statistically significant difference (p < 0.001). The majority of solicited systemic AEs were considered to be causally related to the study vaccine. The duration of both solicited systemic and local AEs was similar in both groups. Taken together, the data indicate that AD subjects have slightly more solicited AEs with more intense reactions towards MVA than healthy subjects.

Table 4. Subjects Experiencing at Least One Solicited Local Adverse Event (8-Day Follow-Up Period after Vaccination, FAS, N = 632).

Table 5. Subjects Experiencing at Least One Solicited Systemic Adverse Events (8-Day Follow-Up period After Vaccination, FAS, N = 632).

Unsolicited adverse events.

Unsolicited AEs experienced by ≥ 2% of subjects in any study group are presented in Table 6. A similar percentage of subjects reported at least one unsolicited AE (68.6% in subjects with diagnosed AD and 64.5% in healthy subjects), with most events being classified as 'systemic disorders and administration site conditions'. This was mostly due to a high rate of 'injection site pruritus', which was reported by 28.6% of the subjects in the AD group and by 17.0% of the healthy subjects, a statistically significant difference (p < 0.001). Rashes were observed only in isolated cases, with no trend towards a specific treatment group. In addition, AEs classified as 'skin and subcutaneous tissue disorders' were reported more frequently by AD than by healthy subjects (p = 0.002). Overall, more than two thirds of all unsolicited AEs in both groups were of Grade 1 intensity and Grade 3 AEs were reported in both groups with a similar frequency. Unsolicited AEs assessed as being probably or definitely related to the study vaccine occurred in 31.8% of the AD and 22.5% of the healthy subjects (p = 0.007) and they were usually associated with direct injection site reactions. Overall AD subjects had more skin reactions possibly, probable or definite related to the vaccine than healthy subjects, but these reactions were mostly mild or moderate and did not prevent daily activities.

Table 6. Subjects Experiencing at Least One Unsolicited Adverse Events (Occurring in ≥ 2% of Subjects in any Study Group, FAS, N = 632).

Cardiac events.

To determine the cardiac risk, any cardiac symptom, ECG change determined to be clinically significant, cardiac enzyme or troponin I level elevated above normal, was noted as an AESI. When AESI persisted, or if clinically indicated, the subjects were referred to a cardiologist. A transient increase in troponin I was measured for about the same percentage of subjects diagnosed with AD (15.4%) as for healthy subjects (13.1%, Table 6).

In the AD group, four subjects presented with one AESI each other than an increased Troponin I: Tachycardia and QTc prolongation of >440 msec, both assessed as unlikely related, and T wave inversion and palpitations, both considered possibly related to the study vaccine. The case of palpitations was assessed as benign by a cardiologist and symptoms resolved successfully after treatment with atenolol. A precise cause for the palpitations was not identified; however tests indicated that the subject’s thyroid values were at the upper limit of normal and the ongoing concomitant medication with albuterol may have contributed. A second case of tachycardia, assessed as unrelated to the study vaccine, was recorded for one healthy subject at a follow-up visit. The heart rate had returned to normal at an additional visit. In total, four subjects were referred to a cardiologist, but with the exception of the case mentioned above, no cardiac treatment was prescribed. All events resolved without sequelae.

Serious adverse events (SAEs).

During the active study period, one subject with active AD and two healthy subjects experienced a total of four SAEs. Three of them (head injury, loss of consciousness, panic attack) were assessed as not related to the study vaccine. One SAE (extraocular muscle paresis) occurring 8 days after the second vaccination was noted as probably related to the vaccine. The subject was a 28 year old healthy woman who complained of constant mixed horizontal and vertical diplopia. The ophthalmologist treated her with carbamazepine and vitamin B complex and the event resolved without sequelae. After Week 8, one healthy subject and two subjects with active AD experienced a total of four SAEs (pneumonia, asthma attack in a subject with a history of asthma, and two events of psychoneurotic disorder in one subject); all were assessed as not related to the study vaccine.


ELISA and PRNT seroconversion rates were similar for both groups at all time points (Fig 2A and 2B, Table 7). ELISA seroconversion rates peaked two weeks post second vaccination when 97.2% of AD subjects and 98.1% of healthy subjects had seroconverted. The primary endpoint of the trial was met because the ELISA seroconversion rate for AD subjects two weeks post second vaccination was non-inferior compared to that for healthy subjects. PRNT seroconversion rates peaked two weeks post second vaccination with 88.0% of the AD group and 86.0% of the healthy group seroconverting. The PRNT seroconversion rate for AD subjects two weeks post second vaccination was also non-inferior compared to that for healthy subjects.

Fig 2. Seroconversion.

Seroconversion rates were determined by vaccinia-specific ELISA (A) and PRNT (B). Data set is FAS (full analysis set), N = 632 (for Week 32 N = 235). Error bars represent upper and lower confidence intervals. Vaccinations were given at Week 0 and Week 4. AD = atopic dermatitis.

Table 7. Seroconversion rates for ELISA and PRNT at all post-baseline visits (FAS, N = 632).

GMTs determined by ELISA were similar for both groups at all visits, reaching a peak of 516.0 at Week 6 for the AD group, which was non-inferior to the peak of 508.8 for the healthy group (Fig 3A, Table 8) (p<0.0001). The peak GMT determined by PRNT for the AD group was non-inferior compared to that of the healthy group at Week 6 (GMT of 43.0 and 38.5 in the AD and healthy groups respectively, (p<0.0001)). Again, the GMTs on all other visits were similar for both groups. Combining both groups, there was a statistically significant correlation between ELISA and PRNT results (Fig 3B) at all time points, with Spearman correlation coefficients ranging from between 0.40 to 0.65 at the different time points. Maximum correlation was at the peak visit two weeks after the second vaccination.

Fig 3. Antibody Titers.

Geometric mean titers determined by vaccinia-specific ELISA (A) or PRNT (B). Data set is FAS (full analysis set), N = 632 (for Week 32 N = 235). Error bars represent upper and lower confidence intervals. Vaccinations were given at Week 0 and Week 4. AD = atopic dermatitis.

Table 8. GMT for ELISA and PRNT at all post-baseline visits (FAS, N = 632).


This Phase II trial confirmed the observations from a Phase I trial that the safety and immunogenicity of MVA in individuals with active AD or a history of AD is similar to healthy individuals [23]. Unsolicited and solicited AEs reported during the study were consistent with results obtained from previously completed clinical trials with MVA [1923].

The number of serious AEs was low, just one serious AE involving transitory ocular paralysis was assessed as probably related to the study vaccine. The impairment was limited to the extraocular inferior rectal muscle which recovered without sequelae. To date, no other similar event has been observed following administration of MVA. No other serious AE with a possible, probable or definite causal relationship occurred in the AD group, indicating with a 95% certainty that the rate of such events in subjects with AD is less than 1%.

Not surprisingly, AD subjects were more likely to develop 'injection site erythema' and 'injection site swelling'. However, there was no indication that vaccination with MVA worsened the intensity of AD. Some subjects in the AD group experienced a flare-up or worsening of their disease during the study, while others with active AD at screening did not show any active AD at the end of the study. This may reflect the nature of the underlying disease, which shows episodes of exacerbations as well as periods of remission [31].

While the burden of AD in the adult population is not as well characterized as in pediatric populations, based on SCORAD the population enrolled in this study was similar to the distribution of AD reported in pediatric populations [32,33]. Although individuals with severe AD (SCORAD >30) were per protocol excluded from this trial, there was no signal in this trial to suggest that MVA would not be safe for them. Historically, the severity of AD has not been associated with increased occurrence or greater severity of complications resulting from smallpox vaccination. Both persons with a history of active disease or with active disease are at risk of developing EV, suggesting an underlying “genetic” susceptibility might be the most important factor for vaccination side-effects [6]. As MVA does not replicate in human cells and is administered subcutaneously rather than by scarification, MVA vaccination should not result in any of the other adverse events associated with virus replication. While the trial was not large enough to draw definitive conclusions, it is reassuring that no case of EV or any other replication-associated adverse event occurred.

Smallpox vaccination using replicating vaccines conducted in recent years resulted in cases of myopericarditis that clustered during the second week after vaccination. The occurrence of vaccine associated myopericarditis was confirmed at a rate of 5.73 per 1,000 vaccinia-naïve vaccinees who received ACAM2000 [34,35]. Cardiac monitoring during the present trial revealed no cardiac risks related to the use of MVA, consistent with published data on cardiac monitoring following administration of MVA [36]. The vast majority of cardiac related events were Grade 1 events ('troponin I increased') that were transient and not connected to abnormal ECG findings or any cardiac symptom [37].

The trial confirmed that AD subjects were able to generate humoral vaccinia-specific immune responses at levels similar to healthy subjects, confirming earlier results in subjects with mild AD [31]. Although individuals with severe AD (SCORAD >30) were not under investigation in this the trial, it is likely that they would mount a comparable immunological response, as there is little evidence suggesting that AD has any measurable impact on immunological responses to vaccines delivered subcutaneously [38].

In summary, vaccination with MVA was equally well tolerated in both populations and elicited a robust vaccinia-specific immune response. The observation that vaccination does not have any discernible impact on the status or severity of AD suggests that MVA may represent a safer alternative to replication-competent vaccinia vaccines for individuals with AD.

Supporting Information

S1 Checklist.


S1 Fig. This is the Seroconversion ELISA PPS.


S2 Fig. This is the Seroconversion PRNT PPS.


S3 Fig. This is the GMT ELISA PPS.


S4 Fig. This is the GMT PRNT PPS.


S5 Fig. These are the figure legends for the supplemental figures.


S1 IRB. These are the IRB approvals for the sites in Mexico.


S2 IRB. These are the IRB listings.


S3 IRB. This is the IRB approval for Dr. Greenberg’s site.


S1 Patents.


S1 Protocol.


S1 Table. These are adverse events tables.


S2 Table. This shows the PRNT and ELISA Titers of Subjects not in PPS.



The following Investigators and Clinical Trials Sites recruited subjects for this trial: Richard N Greenberg, University of Kentucky, Lexington, KY, USA (RNG is grateful to Elizabeth Plummer, Dana Hargis, Heather Flynn, Debra Plummer, Malissia VanHook, Connie Gerardot, Stephen Sitzlar and the UK-CCTS clinic (the UK-CCTS clinic is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1TR000117) at the University of Kentucky for the recruitment and care of subjects.); Yadira Hurley, Saint Louis University, St Louis, MO, USA; Dinh V Dinh, Rx Clinical Research, Garden Grove, CA, USA; Serena Mraz, Solano Clinical Research, Petaluma, CA, USA; Javier Gomez Vera, Hospital Regional Lic. Adolfo Lopez Mateos, Mexico City, Mexico; Brandon Essink, Merdian Clinical Research, Omaha, NE, USA; Tyler Wadsworth, Sundance Clinical Research, St. Louis, MO, USA; Juan Galán Herrera, Operadora MSB CIF-BIOTEC, Ciudad de México, México; Dowling Stough, Burke Pharmaceutical Research, Hot Springs, AR, USA; Anne Laumann, Northwestern University, Chicago, IL, USA; Sandra González Diaz, Centro Regional de Alergia e Inmunología, Monterrey, México; Phoebe Rich, Oregon Dermatology and Research Center, Portland, OR, USA; Stefanie Lundell, Alta Clinical Research, Tucson, AZ, USA; Eduardo Tschen, Academic Dermatology Associates, Albuquerque, NM, USA; Araceli Hernandez Garcia, Unidad de Investigación en Salud de Chihuahua, Chihuahua, México; John Tu, Dermatology Associates of Rochester, Rochester, NY, USA; David Kaplan, Dr. Kaplan's Medispa Dermatology PC; Overland Park, KS, USA; Maria Mata Lara, Hospital Angel Leañol, Zapopan, Mexico; Steven Davis, Dermatology Clinical Research, San Antonio, TX, USA; Maria Rojo Gutiérrez, Hospital Juárez de México, Ciudad de México, México; Williams Abramovits, Dermatology Treatment & Research Center, Dallas, TX; USA;

Data collection, management and analyses were performed by Kendle International (Cincinnati, OH). Design and conduct of the trial were managed by Bavarian Nordic A/S. The assistance of the following team members is appreciated: Gabriela Mancera (Kendle), Karla Guzman (Kendle), Monika Herrmann (Kendle), Petra Hanel (Kendle), Jane Maclennan (BN) and Eva Wagner (BN).

We thank Carol Ostrye and Steve Heyse from NIAID.

This study was funded by NIAID contract#N01-AI–40072.

We wish to gratefully acknowledge the trial participants that devoted their time and effort to this research endeavor.

Parts of the data have been presented at the following meetings:

69th Annual Meeting of the American Association of Dermatology in February 2011 (New Orleans): A new smallpox vaccine for people with atopic dermatitis (AD): protection for the unprotected?

2nd Israeli International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters (IPRED) in January 2012 (Tel Aviv, Israel) Safety And Immunogenicity Of The Third Generation Smallpox Vaccine IMVAMUNE In Subjects With Atopic Dermatitis.

Author Contributions

Conceived and designed the experiments: DB AK NA TPM PY. Performed the experiments: RNG YH DVD SM JGV. Analyzed the data: PY. Contributed reagents/materials/analysis tools: TPM DS. Wrote the paper: RNG YH SR GV RN PC.


  1. 1. Henderson DA. Smallpox: Clinical and epidemiologic features. Emerg Infect Dis 1999 Jul;5(4):537–9. pmid:10458961
  2. 2. Artenstein AW, Grabenstein JD. Smallpox vaccines for biodefense: need and feasibility. Expert Rev Vaccines 2008 Oct;7(8):1225–37. pmid:18844596
  3. 3. Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975 Mar;55(3):342–7. pmid:238178
  4. 4. Lane JM, Frederick L, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969 Nov 27;281(22):1201–8. pmid:4186802
  5. 5. Lane JM, Frederick L, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: Results of ten statewide surveys. J Infect Dis 1970 Oct;122(4):303–9. pmid:4396189
  6. 6. Engler RJ, Kenner J, Leung DY. Smallpox vaccination: Risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol 2002 Sep;110(3):357–65. pmid:12209080
  7. 7. Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, Stein SL, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008 May 15;46(10):1555–61. pmid:18419490
  8. 8. Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE, et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006 Mar;24(3):341–8. pmid:16546102
  9. 9. Copeman P, Wallace HJ. Eczema Vaccinatum. Br Med J 1964;(5414):906–8. pmid:14185655
  10. 10. Waddington E, Bray P, Evans A, Richards I. Cutaneous complications of mass vaccination against smallpox in South Wales 1962. Trans St Johns Hosp Dermatolo Soc 1964;50:22–42.
  11. 11. Neff JM, Lane JM, Fulginiti VA, Henderson DA. Contact vaccinia-transmission of vaccinia from smallpox vaccination. JAMA 2002 Oct 16;288(15):1901–5. pmid:12377090
  12. 12. Hanifin JM, Reed ML. A population-based survey of eczema prevalence in the United States. Dermatitis 2007 Jun;18(2):82–91. pmid:17498413
  13. 13. Naleway AL, Belongia EA, Greenlee RT, Kieke BA Jr, Chen RT, Shay DK. Eczematous skin disease and recall of past diagnoses: implications for smallpox vaccination. Ann Intern Med 2003 Jul 1;139(1):1–7. pmid:12834312
  14. 14. Moberg C, Meding B, Stenberg B, Svensson A, Lindberg M. Remembering childhood atopic dermatitis as an adult: factors that influence recollection. Br J Dermatol 2006 Sep;155(3):557–60. pmid:16911281
  15. 15. Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002 Mar;5(2):84–90. pmid:11990216
  16. 16. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr 1974 Nov 22;99(47):2386–92. pmid:4426258
  17. 17. Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol [B] 1978 Dec;167(5–6):375–90.
  18. 18. Mayr A, Hochstein-Mintzel V, Stickl H. Passage history, properties, and use of attenuated vaccinia virus strain MVA. Infection 1975;3(1):6–14.
  19. 19. Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007 Dec 12;25(51):8562–73. pmid:18036708
  20. 20. Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von KA, et al. Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects. J Infect Dis 2013 Mar;207(5):749–58. pmid:23225902
  21. 21. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006 Mar 15;24(12):2065–70. pmid:16337719
  22. 22. von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010 Feb 3;28(5):1209–16. pmid:19944151
  23. 23. von Sonnenburg F, Perona P, Darsow U, Ring J, Krempelhuber A, Vollmer J,et al. Safety and Immunogenicity of Modified Vaccinia Ankara as a Smallpox Vaccine in People with atopic dermatitis. Vaccine 2014, 32: 5696–5702 pmid:25149431
  24. 24. Stittelaar KJ, van AG, Kondova I, Kuiken T, van Lavieren RF, Pistoor FH, et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 2005 Jun;79(12):7845–51. pmid:15919938
  25. 25. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004 Mar 11;428(6979):182–5. pmid:15014500
  26. 26. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 2008 May;118(5):1776–84. pmid:18398511
  27. 27. Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A 2008 Aug 5;105(31):10889–94. pmid:18678911
  28. 28. Damon IK, Davidson WB, Hughes CM, Olson VA, Smith SK, Holman RC, et al. Evaluation of smallpox vaccines using variola neutralization. J Gen Virol 2009 Apr 1.
  29. 29. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195(1):10–9. pmid:9267730
  30. 30. Overton E, Stapleton J, Frank I, Hassler S, Goepfert P, Barker D, et al. Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An open-Label, Controlled Clinical Phase II Trial. OFID 2015 1–10.
  31. 31. Leung DY, Bieber T. Atopic Dermatitis. Lancet 2003 Jan 11;361(9352):151–60. pmid:12531593
  32. 32. Boehme M, Svensson A, Kull I, Nordvall S, Wahlrgren C. Clinical features of atopic dermatitis at two years of age: a prospective, population-based case-control study. Acta Derm Venereol 2001;81(3):193–7. pmid:11558876
  33. 33. Kim M, Kang T, Cho E, Kim H, Min J, Park H, et al. Prevalence of atopic dermatitis among Korean adults visiting health service center of the Catholic Medical Center in Seoul Metropolitan Area, Korea. J Korean Med Sci 2010;25(12):1828–30. pmid:21165305
  34. 34. Arness MK, Eckart RE, Love SS, Atwood JE, Wells TS, Engler RJ, et al. Myopericarditis following smallpox vaccination. Am J Epidemiol 2004 Oct 1;160(7):642–51. pmid:15383408
  35. 35. Nalca A. ACAM2000: The new smallpox vaccine for United States Strategic National Stockpile. Drug Design Development and Therapy 2010;4:71–9.
  36. 36. Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, et al. Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia ankara vaccines: a systematic review. PLoS ONE 2013;8(1):e54407. pmid:23349878
  37. 37. Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance. Chest 2004;125(5):1877–84. pmid:15136402
  38. 38. Scott JE, Elkhal A, Freyschmidt EJ, MacArthur DH, McDonald D, Howell MD, et al. Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation. J Allergy Clin Immunol 2007 Dec;120(6):1382–8. pmid:17889291